Besides genetic alterations, lymphoma B-cell growth is controlled by constitutively active protein kinases as demonstrated by the successful therapeutic strategy targeting Bruton’s Tyrosine Kinase (BTK) or Phosphoinositide 3 kinase (PI3K) in non-Hodgkin lymphomas (9). This evidence concerns the gene BTK and lymphoma.